Sera Prognostics, Inc. (SERA) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $2.14. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is SERA = $5 (+133.6% upside).
Valuation: SERA trades at a trailing Price-to-Earnings (P/E) of -3.6 (S&P 500 average ~25).
Financials: revenue is $81,000, -18.5%/yr average growth. Net income is $32M (loss), growing at +10.1%/yr. Net profit margin is -39417.3% (negative). Gross margin is -102.5% (-130.5 pp trend).
Balance sheet: total debt is $2M against $75M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 1.69 (strong liquidity). Debt-to-assets is 2.3%. Total assets: $102M.
Analyst outlook: 4 / 5 analysts rate SERA as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
